Difference between revisions of "Bone sarcoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf" to "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418")
m (Text replacement - "http://www.esmo.org/" to "https://www.esmo.org/")
 
(One intermediate revision by the same user not shown)
Line 17: Line 17:
 
=Guidelines=
 
=Guidelines=
 
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
 
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
==[http://www.esmo.org/ ESMO]/EURACAN/GENTURIS/PaedCan==
+
==[https://www.esmo.org/ ESMO]/EURACAN/GENTURIS/PaedCan==
 
*'''2021:''' Strauss et al. [https://doi.org/10.1016/j.annonc.2021.08.1995 Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/34500044/ PubMed]
 
*'''2021:''' Strauss et al. [https://doi.org/10.1016/j.annonc.2021.08.1995 Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/34500044/ PubMed]
 
**'''2018:''' Casali et al. [https://doi.org/10.1093/annonc/mdy310 Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/30285218/ PubMed]
 
**'''2018:''' Casali et al. [https://doi.org/10.1093/annonc/mdy310 Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/30285218/ PubMed]
Line 24: Line 24:
 
**'''2010:''' Hogendoorn et al. [https://doi.org/10.1093/annonc/mdq223 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/20555083/ PubMed]
 
**'''2010:''' Hogendoorn et al. [https://doi.org/10.1093/annonc/mdq223 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/20555083/ PubMed]
  
==[https://www.nccn.org/ NCCN]==
+
==NCCN==
 
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418 NCCN Guidelines - Bone Cancer]
 
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418 NCCN Guidelines - Bone Cancer]
 
*'''2013:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2013.0088 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/23744868/ PubMed]
 
*'''2013:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2013.0088 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/23744868/ PubMed]

Latest revision as of 17:51, 23 June 2024

Section editor
Elizabethdavis2.jpg
Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN, USA
0 regimens on this page
0 variants on this page


Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the category page for links to other sarcoma types or use one of these links:

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ESMO/EURACAN/GENTURIS/PaedCan

NCCN

Chondrosarcoma, all lines of therapy

Undifferentiated pleomorphic sarcoma (UPS) of bone, all lines of therapy